Portal de Periódicos da CAPES

A Phase II Trial of Uracil–Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma

2005; Oxford University Press; Volume: 35; Issue: 8 Linguagem: Inglês

10.1093/jjco/hyi131

1465-3621

Masafumi Ikeda, Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Junji Furuse, Hiroshi Ishii,

Gallbladder and Bile Duct Disorders

Background: Uracil–tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The aim of this study was to evaluate the antitumor activity and toxicity of UFT in chemotherapy-naive patients with advanced biliary tract carcinoma.